Product
hAd5-S-Fusion+N-ETSD
2 clinical trials
1 indication
Indication
COVID-19Clinical trial
A Phase 2/3, Placebo-Controlled, Randomized, Observer-Blind Study To Evaluate the Safety, Tolerability, Immunogenicity, and Efficacy of a 2nd Generation E1/E2B/E3-Deleted Adenoviral COVID-19 Vaccine: The TCELLVACCINE TRIALStatus: Completed, Estimated PCD: 2022-06-23
Clinical trial
Phase 1b Open-Label Study of the Safety, Reactogenicity, and Immunogenicity of a Prophylactic COVID-19 Vaccination Using a 2nd Generation (E1/E2B/E3-Deleted) Adenoviral Platform in Healthy South African Adults (ProVIVA-SA-1)Status: Active (not recruiting), Estimated PCD: 2023-09-01